News Releases

Date Title
02/21/2012 Summary ToggleEnanta Enters into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV
10/13/2011 Summary ToggleEnanta Awarded up to $42.7 Million NIAID Contract to Develop a Novel Broad Spectrum Bicyclolide Antibiotic
09/26/2011 Summary ToggleEnanta’s Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover’s Top 10 Infectious Disease Projects to Watch
04/04/2011 Summary ToggleAbbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
11/01/2010 Summary ToggleAbbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/R for Treatment of Hepatitis C
03/02/2010 Summary ToggleAbbott and Enanta Announce Advancement of Hepatitis C Collaboration-- Initiation of Phase 2 Clinical Trial Investigating Three Individual HCV Antivirals
03/02/2010 Summary ToggleEnanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program
02/18/2009 Summary ToggleAbbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor